Articles by Mike Brown
Born and raised in California. Mike studied business law and has been in the credit industry for over half a decade. Mike has been extremely active in the industry working directly with large financial institutions such as American Express. Prior, Mike held various management positions and developed strategic relationships with business such as Oakley. Investing started as a a hobby for Mike. Due to his recent success in the market he has amassed a fortune as a private self investor. His favorite sector is Biotech and through the knowledge Mike has gained over the years he will help you gain an insight into the industry and its competitive dynamics.
Santarus, Inc. (NASDAQ:SNTS) expects the FDA to decide by December 4, 2009 regarding its NDA for ZEGERID tablet product. A NDA (New Drug Application) for DM-1796 is also expected to be filed with the FDA the …
Paradigm Medical Industries, Inc. (OTC:PDMI) is currently breaking out and is up about 45% today on good volume. The stock was consolidating the last few weeks after a 700% gain. Now that the stock is consolidated …
Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (PINK: NRIFF), a Canadian drug development company, both have an action date of today 11/4/2009 from the Food and Drug Administration …
It has been almost a month since NavStar Technologies Inc (PINK:NVSR) announced a “Major Breakthrough” in the Middle east on October 8, 2009. They anounced that “Details will be provided to shareholders in the next 5 to …
Lifeline Biotech (Public, PINK:LLBO) reported today about the status of their First Warning System™ 510(k) FDA application. The consulting firm, Lifeline Biotech used to submit the FDA application, advised that the “FDA is running anywhere from …
One of the leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, Aastrom Biosciences Inc has announced that they have received a Staff Determination letter from the NASDAQ stock market which …
In the first quarter of 2009 Nanosphere, Inc. (NSPH) filed a de novo 510(k) submission for a hereditary hemochromatosis (“HFE”) genetic test. Mutations of this HFE gene are the leading cause of an iron overload disease. Nanosphere’s test …
It has been over a month since the FDA last informed Hemispherx Biopharma (AMEX:HEB) “it may require up to 1-2 additional weeks” to make its decision on HEB’s drug Ampligen, a treatment for Chronic Fatigue …
